SAN FRANCISCO, CA–(Marketwired – May 05, 2016) – Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 monoclonal antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease and skin disorders. Immune Pharma also has a growing presence in immuno-oncology, with the goal to create a fully sustained oncology subsidiary in the near future. In this article for The Life Sciences Report, analyst Jason Napodano digs into the company’s pipeline and investment potential.
Included in this article is: Immune Pharmaceuticals Inc. (NASDAQ: IMNP).
Immune Pharmaceuticals Inc. is currently enrolling patients in two Phase 2 clinical trials with bertilimumab for the treatment of ulcerative colitis and bullous pemphigoid (BP). A third Phase 2 program in atopic dermatitis is planned for later in 2016.
Data from the Phase 2a program in BP is expected in late 2016. This open-label, proof-of-concept, single group study targets 10-15 adult patients with newly diagnosed, moderate to extensive BP (NCT0222146). Patient recruitment is occurring at two medical centers in Israel, with plans to open as many as six sites in the U.S. during Q2/16 or Q3/16. Additional sites in Europe are expected to come online shortly, which should…
Continue reading this article: Delving Deep into Immune Pharmaceuticals’ Diverse Pipeline
About Streetwise Reports — The Life Sciences Report
Investors rely on The Life Sciences Report
to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
Immune Pharmaceuticals Inc. is a sponsor of Streetwise Reports. Jason Napodano is wholly responsible for the validity of the statements. Statement and opinions expressed are the opinions of Jason Napodano and not of Streetwise Reports or its officers. This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Please see Streetwise Reports’ terms of use and full legal disclaimer.
Jim Patrick
Email contact